Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
PHASE3
The standard treatment for patients with acute myeloid leukemia (AML) with ...
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
PHASE3
Acute Myeloid Leukaemia (AML) is an aggressive and rare cancer of myeloid c...
A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive Chemotherapy
PHASE2
The purpose of this study is to find out how well the study drug IPN60340 w...
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
PHASE2
Cancer is a condition where cells in a specific part of the body grow and r...
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
PHASE2
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates...
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
PHASE3
Myelodysplastic Syndrome (MDS) is a group of disorders that gradually affec...
Status
Active Not Recruiting
Location
Duplicate_Providence Medical Foundation /ID# 222633